These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38318106)

  • 1. Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs.
    Nakazato I; Shiomi T; Oyama K; Matsuno A; Inomoto C; Yoshiyuki Osamura R
    Acta Histochem Cytochem; 2023 Dec; 56(6):121-126. PubMed ID: 38318106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.
    Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical presentation of PIT1 positive pituitary neuroendocrine tumor immunonegative for growth hormone, prolactin, and thyroid stimulating hormone with analysis of clinical and immunostaining dissociation.
    Hong S; Shinya Y; Trejo-Lopez JA; Gruber LM; Erickson D; Bendok BR; Chaichana KL; Atkinson JL; Marino MJ; Donaldson AM; Stokken JK; Westphal SA; Chang AY; Samson SL; Choby GW; Van Gompel JJ
    Clin Neurol Neurosurg; 2024 Jan; 236():108075. PubMed ID: 38056042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
    Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
    Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.
    Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S
    Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies.
    Chinezu L; Vasiljevic A; Jouanneau E; François P; Borda A; Trouillas J; Raverot G
    Hum Pathol; 2014 Jan; 45(1):71-7. PubMed ID: 24182563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.
    Peng G; Guo C; Lv Y; Li D; Zhou L; Shen R; Chen Y; Zheng X; Sun Z; Zheng H; Long M
    BMC Endocr Disord; 2022 Dec; 22(1):325. PubMed ID: 36539773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.
    Dumitriu-Stan RI; Burcea IF; Dobre R; Nastase VN; Ceausu RA; Raica M; Poiana C
    Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
    Nagamine T; Fukuda I
    No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
    Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Tips of the Endocrine Assessment in the Case of Pituitary Tumor].
    Terasaka T; Inagaki K
    No Shinkei Geka; 2023 Jul; 51(4):625-633. PubMed ID: 37491059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
    Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
    Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptors: from signaling to clinical practice.
    Theodoropoulou M; Stalla GK
    Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro regulation of pituitary transcription factor-1 (Pit-1) by changes in the hormone environment.
    González-Parra S; Chowen JA; García-Segura LM; Argente J
    Neuroendocrinology; 1996 Jan; 63(1):3-15. PubMed ID: 8839350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of prolactin in clinically non-functioning pituitary adenomas.
    Winczyk K; Toszek J; Swietoslawski J; Wojtczak E; Pawlikowski M
    Folia Histochem Cytobiol; 2020; 58(2):90-95. PubMed ID: 32597492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
    Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
    Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB
    Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial seeding of pituitary neuroendocrine tumor: a case report.
    Deng C; Gu L; Sun J; Feng M; Bao X
    Gland Surg; 2024 Jun; 13(6):1108-1115. PubMed ID: 39015715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.